Therapy of experimental herpes simplex encephalitis with aciclovir in mice

N. H. Park, D. Pavan-Langston, S. L. McLean, Daniel Albert

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

This report is concerned with the capacities of aciclovir to protect mice challenged intracerebrally with multiple lethal doses of type 1 herpes simplex virus and to control multiplication of this virus in the brain. With treatment initiated 12 hr after inoculation and continued for 4 consecutive days, aciclovir administered subcutaneously in daily doses ranging from 40 to 100 mg/kg led to 21-day survival rates of from 33 to 73% and reduced virus titers by 1 to 1/2 x 4 logs on postchallenge day 8. The therapeutic accomplishments of the 100-mg/kg doses of aciclovir were comparable to those of 1,000-mg/kg doses of vidarabine (9-β-D-arabinofuranosyladenine); however, as measured by impact on body weight, aciclovir was better tolerated than vidarabine at these similarly effective doses.

Original languageEnglish (US)
Pages (from-to)775-779
Number of pages5
JournalAntimicrobial Agents and Chemotherapy
Volume15
Issue number6
DOIs
StatePublished - Jan 1 1979
Externally publishedYes

Fingerprint

Herpes Simplex Encephalitis
Investigational Therapies
Acyclovir
Vidarabine
Human Herpesvirus 1
Viral Load
Body Weight
Viruses
Brain
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Therapy of experimental herpes simplex encephalitis with aciclovir in mice. / Park, N. H.; Pavan-Langston, D.; McLean, S. L.; Albert, Daniel.

In: Antimicrobial Agents and Chemotherapy, Vol. 15, No. 6, 01.01.1979, p. 775-779.

Research output: Contribution to journalArticle

Park, N. H. ; Pavan-Langston, D. ; McLean, S. L. ; Albert, Daniel. / Therapy of experimental herpes simplex encephalitis with aciclovir in mice. In: Antimicrobial Agents and Chemotherapy. 1979 ; Vol. 15, No. 6. pp. 775-779.
@article{df6720612ca94ffea715d92387f7854f,
title = "Therapy of experimental herpes simplex encephalitis with aciclovir in mice",
abstract = "This report is concerned with the capacities of aciclovir to protect mice challenged intracerebrally with multiple lethal doses of type 1 herpes simplex virus and to control multiplication of this virus in the brain. With treatment initiated 12 hr after inoculation and continued for 4 consecutive days, aciclovir administered subcutaneously in daily doses ranging from 40 to 100 mg/kg led to 21-day survival rates of from 33 to 73{\%} and reduced virus titers by 1 to 1/2 x 4 logs on postchallenge day 8. The therapeutic accomplishments of the 100-mg/kg doses of aciclovir were comparable to those of 1,000-mg/kg doses of vidarabine (9-β-D-arabinofuranosyladenine); however, as measured by impact on body weight, aciclovir was better tolerated than vidarabine at these similarly effective doses.",
author = "Park, {N. H.} and D. Pavan-Langston and McLean, {S. L.} and Daniel Albert",
year = "1979",
month = "1",
day = "1",
doi = "10.1128/AAC.15.6.775",
language = "English (US)",
volume = "15",
pages = "775--779",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "6",

}

TY - JOUR

T1 - Therapy of experimental herpes simplex encephalitis with aciclovir in mice

AU - Park, N. H.

AU - Pavan-Langston, D.

AU - McLean, S. L.

AU - Albert, Daniel

PY - 1979/1/1

Y1 - 1979/1/1

N2 - This report is concerned with the capacities of aciclovir to protect mice challenged intracerebrally with multiple lethal doses of type 1 herpes simplex virus and to control multiplication of this virus in the brain. With treatment initiated 12 hr after inoculation and continued for 4 consecutive days, aciclovir administered subcutaneously in daily doses ranging from 40 to 100 mg/kg led to 21-day survival rates of from 33 to 73% and reduced virus titers by 1 to 1/2 x 4 logs on postchallenge day 8. The therapeutic accomplishments of the 100-mg/kg doses of aciclovir were comparable to those of 1,000-mg/kg doses of vidarabine (9-β-D-arabinofuranosyladenine); however, as measured by impact on body weight, aciclovir was better tolerated than vidarabine at these similarly effective doses.

AB - This report is concerned with the capacities of aciclovir to protect mice challenged intracerebrally with multiple lethal doses of type 1 herpes simplex virus and to control multiplication of this virus in the brain. With treatment initiated 12 hr after inoculation and continued for 4 consecutive days, aciclovir administered subcutaneously in daily doses ranging from 40 to 100 mg/kg led to 21-day survival rates of from 33 to 73% and reduced virus titers by 1 to 1/2 x 4 logs on postchallenge day 8. The therapeutic accomplishments of the 100-mg/kg doses of aciclovir were comparable to those of 1,000-mg/kg doses of vidarabine (9-β-D-arabinofuranosyladenine); however, as measured by impact on body weight, aciclovir was better tolerated than vidarabine at these similarly effective doses.

UR - http://www.scopus.com/inward/record.url?scp=0018764679&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018764679&partnerID=8YFLogxK

U2 - 10.1128/AAC.15.6.775

DO - 10.1128/AAC.15.6.775

M3 - Article

C2 - 475362

AN - SCOPUS:0018764679

VL - 15

SP - 775

EP - 779

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 6

ER -